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Background: We evaluated the effectiveness and safety of a zotarolimus-eluting (ZES) versus a sirolimus-eluting
(SES) coronary stent in a large cohort of patients treated with one of these stents in Western Denmark.
Methods: A total of 6,122 patients treated with ZES (n=2,282) or SES (n=3,840) were followed for up to 27 months.
We ascertained clinical outcomes based on national medical databases.
Results: Incidence of target lesion revascularization (no. per 100 person-years) was 5.3 in the ZES group compared
to 1.9 in the SES group (adjusted hazard ratio (HR)=2.19, 95% confidence intervals (CI): 1.39-3.47; p=0.001). All-cause
mortality was also higher in the ZES group (ZES: 6.3; SES: 3.3; adjusted HR=1.34, 95% CI: 1.05-1.72;
p=0.02), while stent thrombosis (ZES: 1.2; SES: 0.5; adjusted HR=1.98, 95% CI: 0.75-5.23; p=0.14) did not differ
significantly.
Conclusions: In agreement with previously published randomised data, this observational study indicated that the
ZES was associated with an increased risk of death and TLR in a large cohort of consecutive patients.
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Introduction of first-generation drug-eluting stents
(DESs) more than halved the need for target lesion
revascularization (TLR) after coronary stent implant-
ation [1-6]. However, safety concerns have been raised
about the first-generation DESs, especially regarding an
increased risk of late stent thrombosis (>30 days after
stent implantation) [4,7]. The effective inhibition of in-
stent neointima formation by the first-generation DESs
may reduce neointimal coverage of stents, leaving stent
struts as a nidus for late stent thrombosis. Late stent
thrombosis has also been associated with late-acquired
malapposition of stent struts [8] and late vascular in-
flammation (beyond that associated with the initial vas-
cular injury and subsequent healing) [9], both of which* Correspondence: michael.maeng@ki.au.dk
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reproduction in any medium, provided the ormay be related to either the type of drug eluted or the
polymer coating of the stents.
Since the second-generation fast-release zotarolimus-
eluting Endeavor™ stent (ZES) has been shown to in-
duce relatively uniform and complete neointimal cover-
age of the stent struts and to have a lower incidence of
late-acquired incomplete stent apposition [10,11], it
could represent a safer alternative to the first-generation
DESs [12]. Also, the phosphorylcholine coating used for
drug-elution from the ZES could be a safer non-
inflammatory alternative to the polymers used for
sirolimus-eluting and paclitaxel-eluting stents [13,14].
In the current study, based on data from the Western
Denmark Heart Registry (WDHR), we used the sirolimus-
eluting Cypher™ stent (SES) as the comparator stent.
Intravascular ultrasound and angiography studies have
shown that the SES reduced angiographic late lumen
loss and neointima formation assessed by intravascu-
lar ultrasound to a level below detection with these
modalities [1,15-17]. Preclinical studies showed thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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endothelialisation in a rabbit model [18], and that ZES
had a higher grade of inflammation than SES at 30 days
but less inflammation at 90 and 180 days in a porcine
model [19]. Findings from randomised studies, the
largest being the Danish Organisation for Randomized
Trials with Clinical Outcome (SORT OUT) III trial, indi-
cated that ZES, as compared to SES, had lower efficacyTable 1 Patient and procedure characteristics of patients
treated with zotarolimus-eluting (ZES) or sirolimus-
eluting stents (SES)
ZES N = 2,282 SES N = 3,840 P
Age* 67 (59-75)
years
65 (57-73)
years
<0.0001
Male gender 1,645 (72%) 2,869 (75%) 0.024
Family history 807 (44%) 1,455 (46%) 0.17
Smoking 592 (34%) 1,121 (37%) 0.039
Diabetes mellitus 342 (15%) 602 (16%) 0.41
Hypertension 999 (54%) 1,573 (49%) 0.001
Previous coronary
artery
bypass operation
173 (9%) 279 (9%) 0.53
Previous percutaneous
coronary intervention
735 (34%) 1,184 (32%) 0.25
Previous myocardial
infarction
793 (37%) 1,268 (35%) 0.20
Lipid lowering
treatment
1,217 (66%) 1,995 (63%) 0.027
Procedure time* 23 (15-36) min 21 (14-34) min 0.0007
Use of GPIIb/IIIa
inhibitors
626 (27%) 1143 (30%) 0.051
Number of treated
lesions*
1 (1-2) 1 (1-2) 0.175
Number of stents >1 514 (22.5%) 771 (20.1%) 0.023
Total stent length* 18.0
(14.0 - 24.0) mm
18.0
(13.0 - 26.0) mm
0.070
Indication for
percutaneous coronary
intervention
0.025
Stable angina pectoris 924 (41%) 1,610 (42%)
Unstable angina
pectoris/non
ST-segment elevation
myocardial infarction
763 (33%) 1,158 (30%)
ST-segment elevation
myocardial infarction
511 (22%) 946 (25%)
Other 84 (4%) 126 (3%)
Charlson’s comorbidity
index score
0.0003
0 1,368 (60%) 2,475 (65%)
1-2 725 (32%) 1,125 (29%)
3+ 189 (8%) 230 (6%)
* Median (25%-75% quartiles).and was associated with increased risk of early stent
thrombosis and all-cause mortality. As the external
validity of randomised trials is limited by selection bias, it
is important that data from randomised trials can be
reproduced in observational studies [20]. The present
study used the WDHR to compare ZES and SES in order
to see if the randomised SORT OUT III data could be
confirmed in a large cohort of consecutive patients.
Methods
Data extraction
Data for this population-based cohort study were
obtained from the WDHR and national databases. The
WDHR contains patient- and procedure-specific infor-
mation on coronary interventions performed at the three
coronary intervention centers in Western Denmark
(Aarhus University Hospital, Skejby, Aarhus University
Hospital, Aalborg, and Odense University Hospital). The
national databases used in the study included the Danish
Civil Registration System, the National Registry of
Causes of Death, and the Danish National Registry of
Patients, all of which cover the entire region’s population
(approximately 3 million inhabitants, 55% of the Danish
population). A detailed description of these databases
has been published previously [21].
Between August 1, 2005 and October 1, 2007 10,992
patients were treated with percutaneous coronary inter-
vention (PCI) in the region covered by the WDHR. The
study cohort consisted of 6,122 (56%) patients withTable 2 Lesion characteristics of patients treated with
zotarolimus-eluting (ZES) or sirolimus-eluting (SES) stents
ZES N = 3,090
lesions
SES N = 5,095
lesions
P Value
Vessel <0.0001
LM 99 (3.2%) 158 (3.1%)
LAD 1,255 (41%) 2,388 (47%)
LCX 743 (24%) 1,154 (23%)
RCA 991 (32%) 1394 (27%)
Sapheneous vein graft 36 (0.9%) 44 (1.2%) 0.18
Restenotic lesion 87 (2.8%) 74 (1.5%) <0.0001
Stent thrombosis lesion 28 (0.9%) 24 (0.5%) 0.0076
Lesion length* 12 (10-20) mm 15 (10-20) mm 0.027
Lesion type 0.0008
A 659 (21%) 1,100 (22%)
B1 823 (27%) 1,542 (30%)
B2 629 (20%) 1,014 (20%)
C 979 (32%) 1,439 (28%)
Stent length† 19.9 ± 11.9 mm 20.2 ± 11.9 mm <0.0001
Number of stents >1 581 (18.8%) 837 (16.4%) 0.006
* median (25%-75%). † mean ± standard deviation.
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Medtronic, Santa Rosa, Ca) or the SES (Cypher Select or
Cypher Select+; Cordis, Johnson & Johnson, Warren,
NJ). For each patient we included only the first PCI pro-
cedure performed during the study period (the index
procedure). Other drug-eluting stents or a combination
of ZES/SES/other stents were utilized in 1,050 patients
(10%), bare metal stents in 2,125 patients (19%), and bal-
loon angioplasty or other interventions in 1,695 patients
(15%). One-third of the patients included in the present
study (n = 1,868; 31%) were randomised to ZES or SES
as part of the SORT OUT III study, which enrolled
patients between January 2006 and August 2007.Table 3 Hazard ratio (HR) estimates of adverse events among
sirolimus-eluting stents (SES) in western denmark, August 20
Endpoint Period (days) Patients with ZES
No. of events No.
perso
Patient level analysis N = 2,282
Death 0-823 135 6.3
0-30 57 31.0
31-365 62 4.1
366-823 16 3.5
Cardiac death 0-823 57 2.7
0-30 32 17.4
31-365 21 1.4
366-823 4 0.9
Noncardiac death 0-823 53 2.5
0-30 16 8.7
31-365 31 2.1
366-823 6 1.3
Myocardial infarction 31-823 66 3.5
366-823 9 2.1
Target lesion
revascularization
0-823 110 5.3
Stent thrombosis 0-823 26 1.2
0-30 21 11.5
31-365 4 0.3
366-823 1 0.2
Lesion level analysis N = 3,090
Target lesion revascularization 0-823 115 4.0
Stent thrombosis 0-823 28 1.0
0-30 23 9.3
31-365 4 0.2
366-823 1 0.2
*The patient level analyses were adjusted for age, sex, Charlson Comorbidity score, d
stent length, and total no. of stents. The lesion level analyses were adjusted for age,
† Defined as late (>30 days) definite stent thrombosis, myocardial infarction, or deaPost-PCI antiplatelet regimens included lifelong acetyl-
salicylic acid (75 mg daily) and clopidogrel with a load-
ing dose of 300 mg or 600 mg followed by 75 mg daily.
The recommended duration of clopidogrel treatment
was 12 months during the entire study period.
The effectiveness parameter was clinically driven TLR,
defined as any PCI including the stent or within 5 mm
from the proximal or distal stent edge). Safety para-
meters included all-cause mortality, cardiac mortality,
late myocardial infarction (MI; >30 days), and definite
stent thrombosis.
We used the Academic Research Consortium defin-
ition of definite stent thrombosis [22]. We defined newpatients treated with zotarolimus-eluting stents (ZES) or
05 to October 2007
Patients with SES Adjusted HR*
(95% CI)
P Value
/100
n-year
No. of events No./100
person-year
N = 3,840
159 3.3 1.35 (1.05-1.73) 0.018
50 16.0 1.66 (1.10-2.50) 0.016
70 2.4 1.19 (0.82-1.73) 0.388
39 2.5 1.26 (0.67-2.34) 0.475
59 1.2 1.33 (0.89-2.00) 0.183
29 9.3 1.39 (0.80-2.41) 0.229
23 0.8 1.17 (0.59-2.32) 0.711
7 0.4 1.36 (0.31-5.95) 0.687
66 1.4 1.27 (0.87-1.87) 0.217
20 6.4 1.32 (0.65-2.66) 0.467
34 2.1 1.25 (0.75-2.09) 0.397
12 0.8 1.39 (0.50-3.89) 0.532
108 2.5 0.98 (0.69-1.42) 0.964
30 2.0 0.99 (0.43-2.28) 0.992
91 1.9 2.16 (1.36-3.42) 0.001
24 0.5 2.01 (0.76-5.34) 0.159
13 4.2 3.62 (0.92-14.2) 0.065
5 0.2 1.17 (0.18-7.39) 0.870
6 0.4 Not calculable -
N = 5,095
96 1.5 2.48 (1.87-3.27) <0.0001
24 0.4 2.21 (1.26-3.87) 0.006
13 3.1 2.75 (1.38-5.47) 0.004
5 0.1 1.47 (0.39-5.57) 0.568
6 0.3 1.22 (0.14-10.9) 0.857
iabetes mellitus, PCI indication, procedure time, no. of treated lesions, total
sex, diabetes mellitus, PCI indication, procedure time, and stent length.
th from any cause.
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Figure 1 Target lesion revascularization after ZES and SES
implantation in Western Denmark. Clinically driven target lesion
revascularization among patients treated with ZES or SES.
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the index PCI [23] based on admissions and readmis-
sions for MI (ICD-10 codes I21-I21.9) identified from
the Danish National Registry of Patients [21]. We used
the original death certificates obtained from the National
Registry of Cause of Deaths to classify deaths according
to their underlying cause [21]. We ascertained all repeat
coronary interventions (including balloon angioplasty,
stent implantation, and coronary artery bypass grafting)
from the WDHR. These re-interventions were divided
into target vessel revascularization (TVR) and non-TVR.
An endpoint committee examined all TVRs and identi-
fied all TLRs. Subsequently, all TLRs caused by stent
thrombosis were identified by review of the angiogram
and patient files, and the clinical presentation of these
stent thromboses was identified and classified as STEMI,
nonSTEMI, unstable angina pectoris, or stable angina
pectoris.
We retrieved data from the WDHR on potential pre-
dictors of subsequent cardiovascular events, including
patient, procedure, and lesion characteristics. We also
obtained the complete hospitalization history since 1977
for each patient from the Danish National Registry of
Patients until the date of stent implantation, and com-
puted the patients’ Charlson Comorbidity Index scores,
based on 19 major disease categories [24].
Statistical analysis
We computed Aalen-Nelson curves for patients and
lesions and used the life-table method to compute the
cumulative incidence of each outcome. We used Cox
proportional hazard regression to compute HRs as a
measure of the relative risks for each outcome. Since the
hazards were not proportional throughout the follow-up
period, we computed HR estimates within separate time
windows, for which the proportionality assumption held.
The HRs in these sub-analyses reflected the risk among
patients alive and at risk of a given outcome at the start
of each time period. In regression analyses at the patient
level, we controlled for age, sex, Charlson Comorbidity
Index score (3 comorbidity levels), diabetes mellitus, PCI
indication (STEMI, nonSTEMI/unstable angina pectoris,
stable angina pectoris, or other), procedure time, num-
ber of lesions treated, total stent length (i.e., the com-
bined length of stents in all treated lesions), and total
number of stents implanted. In the lesion-specific ana-
lyses (stent thrombosis and TLR) we adjusted for age,
sex, diabetes mellitus, PCI indication, procedure time,
and stent length (i.e., the combined length of stents used
to treat a specific lesion). The subgroup analyses of
patients with and without diabetes were controlled for
the same parameters except diabetes.
Depending on whether data conformed to a normal
distribution, continuous variables were compared by useof the two-sample t-test or the Mann–Whitney test. Cat-
egorical variables were compared using the chi-square
test. We used SAS software version 9.2 (SAS Institute
Inc., Cary, NC, USA) to analyse the data.
Results
Among patients included in this study, 2,282 patients
with 3,090 lesions were treated with ZES and 3,840
patients with 5,095 lesions received SES. All patients
were followed to November 10, 2007, i.e.,. for at least
40 days and up to a maximum of 823 days). The average
follow-up time was 411 days (ZES: 342 days; SES:
452 days). Data on cause of death were not available for
59 patients.
Baseline patient and procedure characteristics pre-
sented in Table 1, and lesion characteristics presented in
Table 2, showed differences between the ZES and SES
groups. The most important were older age, longer pro-
cedure times, higher comorbidity scores, and differences
regarding vessel and lesion types in the ZES group.
The outcome data are provided in Table 3 and the
main outcomes are depicted in Figures 1 and 2. TLR
(5.3% vs. 1.9%; adjusted hazard ratio [HR] 2.16, 95% con-
fidence intervals [CI] 1.36-3.42; p = 0.001) was more
than twice as common in the ZES group at the patient
level, a finding confirmed at the lesion level of analysis.
The safety parameters of all-cause mortality (6.3% vs.
3.3%; adjusted HR 1.35, 95% CI 1.05-173; p = 0.018),
stent thrombosis at the lesion level (1.0% vs. 0.4%;
adjusted HR 2.21, 95% CI 1.26-3.87; p = 0.006), but not
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Figure 2 Safety Outcomes of ZES and SES in the Western Denmark Heart Registry. Risk of all-cause mortality (A), cardiac mortality (B), late
(>30 days) myocardial infarction (C), and stent thrombosis (D) among patients treated with ZES or SES.
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adjusted HR 2.01, 95% CI 0.76-5.34; p = 0.159) were
increased in the ZES group as compared to the SES
group. This was apparently due to an excess of both
early (day 0 to 30) mortality and early stent thrombosis.
There were no significant differences between the two
groups in late safety parameters (day 31 to 823).
Outcomes stratified by presence/absence of diabetes
are presented in Table 4. Patients without diabetes
treated with a ZES had increased risk of target lesion
revascularization (TLR; 4.6% vs. 2.0%; HR 2.14, 95% CI
1.29-3.54; p = 0.0032) and early definite stent thrombosis
at the lesion level (3.4% vs. 1.4%; HR 1.97, 95% CI 1.11-
3.48, p = 0.0202). All other assessed parameters did not
differ significantly. Patients with diabetes treated with a
ZES had increased risk of death (9.9% vs. 4.6%, adjusted
HR 2.03, 95% CI 1.21-3.42; p = 0.0076), cardiac death
(5.4% vs. 1.5%; adjusted HR 3.54, 95% CI 1.59-7.90;p = 0.0020), and TLR (9.8% vs. 1.8%; adjusted HR 3.64,
95% CI 1.10-12.1; p = 0.0350). Lesion level analyses con-
firmed the findings for TLR and indicated a higher risk of
stent thrombosis in the ZES group.
Stent thrombosis accounted for 50 of the 202 TLRs.
These patients were admitted due to ST-segment eleva-
tion myocardial infarction [STEMI; n = 39 (78.0%)],
nonSTEMI [n = 6 (12.0%)], and unstable angina pectoris
[n = 5 (10.0%)].
Discussion
The SORT OUT III trial reported that the ZES was
inferior to SES regarding both efficacy and safety [25].
Although we attempted to randomise routine clinical
care patients (“all-comers”) in SORT OUT III, we
reported that the separate group of patients that were
eligible, but for different reasons not randomised, had
higher 30-day mortality than patients who entered the
Table 4 Hazard ratio (hr) estimates of adverse events among patients with and without diabetes treated with cypher
or endeavour stents
Endpoint Period (days) Diabetic patients Adjusted HR*
(95% CI)
P value Non diabetic patients Adjusted HR*
(95% CI)
P value
(no(no/person year)) Endeavour Cypher Endeavour Cypher
Patient level analysis* N = 342 N = 602 N = 1936 N = 3207
Death 0-823 31 (9.9) 36 (4.6) 2.03 (1.21-3.42) 0.0076 102 (5.6) 122 (3.2) 1.20 (0.90-1.60) 0.20
0-30 12 (43.9) 10 (20.5) 2.13 (0.88-5.15) 0.0942 43 (27.5) 40 (15.3) 1.52 (0.96-2.42) 0.077
31-365 15 (6.9) 18 (3.9) 1.69 (0.80-3.58) 0.1701 47 (3.7) 51 (2.1) 1.09 (0.71-1.68) 0.70
Cardiac death 0-823 17 (5.4) 12 (1.5) 3.54 (1.59-7.90) 0.0020 38 (2.1) 46 (1.2) 0.97 (0.60-1.58) 0.91
0-30 8 (29.3) 4 (8.2) 3.71 (1.03-13.4) 0.0449 22 (14.1) 25 (29.6) 1.09 (0.58-2.03) 0.79
31-365 8 (3.7) 7 (1.5) 3.38 (1.10-10.4) 0.0341 13 (1.0) 15 (0.6) 0.70 (0.29-1.72) 0.44
Noncardiac death 0-823 12 (3.8) 14 (1.8) 1.65 (0.72-3.79) 0.2347 41 (2.3) 52 (1,3) 1.19 (0.77-1.83) 0.44
0-30 4 (14.6) 6 (12.3) 1.22 (0.32-4.61) 0.7678 12 (7.7) 14 (5.4) 1.30 (0.56-3.02) 0.55
31-365 7 (3.2) 7 (1.5) 1.67 (0.51-5.44) 0.3984 24 (1.9) 27 (1.1) 1.18 (0.66-2.10) 0.57
Myocardial infarction 30-823 54 (19.6) 86 (12.7) 1.24 (0.86-1.79) 0.2522 319 (20.4) 543 (16.4) 0.98 (0.85-1.13) 0.79
0-30 41 (168) 68 (155) 1.24 (0.82-1.86) 0.3032 279 (206) 473 (210) 0.99 (0.85-1.16) 0.92
31-365 10 (5.2) 14 (3.5) 0.89 (0.33-2.40) 0.8195 35 (3.2) 49 (2.4) 0.93 (0.56-1.55) 0.79
Composite safety
end point†
30-823 31 (11.1) 48 (6.8) 1.45 (0.87-2.40) 0.1507 105 (6.5) 168 (4.7) 1.00 (0.76-1.31) 0.98
Target lesion
revascularization
0-823 29 (9.8) 14 (1.8) 3.64 (1.10-12.1) 0.0350 81 (4.6) 76 (2.0) 2.14 (1.29-3.54) 0.003
In-stent restenosis 0-823 24 (8.0) 11 (1.4) 7.18 (1.59-32.4) 0.0103 60 (3.4) 56 (1.4) 1.97 (1.11-3.48) 0.020
Stent thrombosis 0-823 5 (1.6) 4 (0.5) - - 21 (1.2) 20 (0.5) 2.92 (0.95-8.93) 0.060
0-30 4 (14.7) 1 (2.0) - - 17 (10.9) 12 (4.6) 5.61 (1.14-27.6) 0.034
31-365 1 (0.5) 1 (0.2) - - 3 (0.2) 4 (0.2) 1.74 (0.23-13.2) 0.59
366-823 0 (0.0) 2 (0.8) - - 1 (0.3) 4 0.3) - -
Lesion level analysis
Target lesion
revascularization
0-823 29 (7.3) 15 (1.4) 5.06 (2.65-9.69) <.0001 86 (3.5) 80 (1.5) 2.08 (1.53-2.85) <0.0001
In-stent restenosis 0-823 24 (6.0) 12 (1.1) 5.06 (2.48-10.3) <.0001 63 (2.5) 60 (1.2) 2.08 (1.45-2.99) <0.0001
Stent thrombosis 0-823 5 (1.2) 4 (0.4) 4.33 (1.02-18.4) 0.047 23 (0.9) 20 (0.4) 2.03 (1.10-3.76) 0.0234
0-30 4 (11.2) 1 (1.5) 11.6 (1.10-122) 0.0413 19 (9.0) 12 (3.5) 2.40 (1.15-4.99) 0.0194
31-365 1 (0.4) 1 (0.2) 1.84 (0.11-30.5) 0.6693 3 (0.2) 4 (0.1) 1.34 (0.29-6.08) 0.7074
366-823 0 (0.0) 2 (0.5) - - 1 (0.2) 4 (0.2) 1.68 (0.17-16.4) 0.66
* The patient level analyses were adjusted for age, sex, Charlson Comorbidity score, PCI indication, procedure time, no. of treated lesions, total stent length, and
total no. of stents. The lesion level analyses were adjusted for age, sex, PCI indication, procedure time, and stent length.
† Defined as late (>30 days) definite stent thrombosis, myocardial infarction, or death from any cause.
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to confirm the generalizability of the SORT OUT III
trial by examination of the entire cohort of patients trea-
ted with a ZES or SES in Western Denmark. Our data
confirm and extend the SORT OUT III results to all
patients treated with ZES and SES in Western Denmark.
As in the SORT OUT III trial, we found that compared
with the SES, use of the ZES increased all-cause mortal-
ity, and produced twice as high rates of TLR and definite
stent thrombosis at medium-term follow-up.
The finding that ZES has higher TLR rates than SES is
concurrent with efficacy analyses based on intravascularultrasound [11], optical coherence tomography [26],
angiography [27], and with clinical results reported from
a Swedish registry [28], a large Korean randomised com-
parison [29], a Korean randomised study in patients with
ST-segment elevation [30], a German randomised study
[31], and the SORT OUT III trial [25]. Although care-
fully performed analyses have shown that late lumen
loss detected by angiography predicted ISR and TLR
[32-34], it has been suggested that minor late loss differ-
ences in the lower end of the late loss scale may not lead
to TLR differences [12,34]. Based on the current data,
the reported in-stent late loss difference between the
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difference in clinically driven TLR.
Definite stent thrombosis constituted 25% of all TLRs,
caused MI in 90% of patients experiencing this adverse
event, and was the cause of all but one TLR-related
STEMI. Even though TLR was a relatively rare event in
the present cohort, definite stent thrombosis was a rela-
tively frequent and high-risk cause of TLR. ZES was
associated with higher rates of definite stent thrombosis
and death during the first 30 days after implantation
whereas we found no overall differences between the
two study stents in late safety outcomes from day 31 on.
In comparison to SES and other available drug-eluting
stents, it is possible that the rapid elution of zotarolimus
from the phosphorylcholine coating creates a milieu in
the stented arterial wall that facilitates early stent throm-
bosis and thus explains the reported increased risk of
early stent thrombosis [25,29]. This hypothesis is sup-
ported by preclinical data describing more vascular in-
flammation with the ZES than the SES at 30 days [19].
With regard to very late (>1 year) stent thrombosis, the
phosphorylcholine coating and the larger neointima for-
mation by the ZES may still reduce the risk of this ad-
verse event when dual antiplatelet therapy is limited to
aspirin only, but our current comparison to SES is in-
conclusive on this issue. A recent study by Serruys et al
[35]. showed that a modified slow-release zotarolimus-
eluting stent (the Resolute™ stent) was non-inferior to
an everolimus-eluting stent. It may thus be release kinet-
ics rather than type of drug that explains the clinical dif-
ferences between ZES and SES implantation.
Patients with diabetes have a higher risk of adverse
events after PCI, which includes an increased rate of TLR
due to excessive neointima formation in diabetic patients
[36]. Our results confirm this hypothesis. In comparison
to SES, we found that ZES-treated patients without dia-
betes had a 2.1-fold higher risk of TLR while ZES-treated
diabetic patients had a 3.6-fold higher risk. These results
accord with results from a Swedish registry and a small
randomized trial [28,37]. Efficacy differences between
various DESs may thus be amplified in diabetic patients.
Our risk estimates are based on population-based
data, largely ruling out referral and diagnostic biases.
Adjustment for a broad range of important prognostic
cardiovascular factors and the fact that 31% of patients
were randomised to the study stent are likely to have
reduced the risk of any major uncontrolled or residual
confounding. Although our study is still limited by po-
tential confounding by indication due to lack of
randomization of the majority of patients, the strength
of this study is that the results are consistent with the
randomised SORT OUT III. The clinical outcome data
were ascertained by use of registry data. In this regard
it is important that the study was performed in a smallEuropean country with a stable population and an accur-
ate registration of the vital status and cause of death of
its citizens. All contacts with the Danish healthcare
system are registered, allowing 100% follow-up. Underre-
porting of events (such as MIs or TLRs during visits
abroad) and misclassifications are possible, but unlikely
to have a major impact on our results, and equally un-
likely to favour one of the two study stents. Another con-
sideration is that the study’s follow-up time was too
short to fully quantify possible risks. It is possible that
longer follow-up would yield different long-term safety
profiles for the two drug-eluting stents. Moreover, our
results with the fast-release Endeavor™ ZES cannot be
extrapolated to the newer slow-release Resolute™ ZES
[35]. Finally, we do not have data on the duration of dual
anti-platelet treatment for the two groups, which theor-
etically might have affected the results.
Conclusions
We conclude that this observational study found that
ZES is inferior to SES, thereby extending randomised
results to a large cohort of consecutive patients.
Abbreviation
CI: Confidence interval; DES: Drug-eluting stent; HR: Hazard ratio;
MI: Myocardial infarction; PCI: Percutaneous coronary intervention;
SES: Sirolimus-eluting stent; SORT OUT: DaniSh Organisation for Randomised
Trials with Clinical OUTcome; STEMI: ST-segment elevation MI; TLR: Target
lesion revascularization; TVR: Target vessel revascularization; WDHR: Western
Denmark Heart Registry; ZES: Zotarolimus-eluting stent.
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